Molecular Imaging As A Critical Tool In Discovery Of The Basis Of Tumour Heterogeneity And Developing Novel Therapies To Overcome Therapeutic Resistance
Grant number: 1108050 | Funding period: 2016 - 2020
Determining treatment options for cancer currently relies on the size and extent of tumour deposits on imaging, combined with a biopsy. However, this approach fails to recognise the ability of tumours to evolve components that are, or become, resistant to treatment. My laboratory uses advanced molecular imaging, targeted biopsies, animal models and genetic analysis to detect and understand the basis of such resistance and thereby develop new, targeted treatments to improve patient outcomes.
Related publications (23)
Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP
Carleen Cullinane, Kelly Waldeck, Laura Kirby, Buck E Rogers, Peter Eu, Richard W Tothill, Rodney J Hicks
Peptide receptor radionuclide therapy (PRRT) is an important treatment option for patients with somatostatin receptor-2 (SSTR2)-ex..
Early Outcomes of Surgery for Carcinoid Heart Disease
Matthew S Yong, Grace Kong, Prakash Ludhani, Michael Michael, John Morgan, Michael S Hofman, Rodney J Hicks, Marco Larobina
BACKGROUND: The prognosis of patients with metastatic neuroendocrine neoplasms (NEN) continues to improve with modern oncological ..
18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors Melanoma and Beyond
Rodney J Hicks, Amir Iravani, Shahneen Sandhu
The complexity of the immune response and diversity of targets challenges conventional conceptual frameworks used in selecting and..
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy
Sue Ping Thang, John Violet, Shahneen Sandhu, Amir Iravani, Tim Akhurst, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Scott G Williams, Rodney J Hicks, Michael S Hofman
BACKGROUND: Prostate-specific membrane antigen (PSMA) is overexpressed in metastatic castration-resistant prostate cancer (mCRPC) ..
Radiosynthesis and preliminary in vivo evaluation of F-18-labelled glycosylated duramycin peptides for imaging of phosphatidylethanolamine during apoptosis
Mohammad B Haskali, Delphine Denoyer, Peter D Roselt, Rodney J Hicks, Craig A Hutton
<p>[<sup>18</sup>F]-Labelled duramycin derivatives incorporating hydrophilic aminogalacturonic acid moieties were prepared as trac..
The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma
Grace Kong, Tess Schenberg, Christopher J Yates, Alison Trainer, Nirupa Sachithanandan, Amir Iravani, Aravind Ravi Kumar, Michael S Hofman, Tim Akhurst, Michael Michael, Rodney J Hicks
Purpose: Germline succinate dehydrogenase (SDHx) mutation carriers, especially SDHB, are at increased risk for malignancy and requ..
The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of F-18-Fluoromethylcholine or Ga-68-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy
Ur Metser, Sue Chua, Bao Ho, Shonit Punwani, Edward Johnston, Frederic Pouliot, Noam Tau, Asmaa Hawsawy, Reut Anconina, Glenn Bauman, Rodney J Hicks, Andrew Weickhardt, Ian D Davis, Greg Pond, AndrewM Scott, Nina Tunariu, Harbir Sidhu, Louise Emmett
Purpose: To assess whether the addition of data from multiparametric pelvic (mpMR) and whole body MR (wbMR) to the interpretation ..
PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment
Amir Iravani, Guy-Anne Turgeon, Tim Akhurst, Jason W Callahan, Mathias Bressel, Sarah J Everitt, Shankar Siva, Michael S Hofman, Rodney J Hicks, David L Ball, Michael P Mac Manus
Cu-64-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy
Rodney J Hicks, Price Jackson, Grace Kong, Robert E Ware, Michael S Hofman, David A Pattison, Timothy A Akhurst, Elizabeth Drummond, Peter Roselt, Jason Callahan, Roger Price, Charmaine M Jeffery, Emily Hong, Wayne Noonan, Alan Herschtal, Lauren J Hicks, Amos Hedt, Matthew Harris, Brett M Paterson, Paul S Donnelly
Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework
Hayley M Reynolds, Scott Williams, Price Jackson, Catherine Mitchell, Michael S Hofman, Rodney J Hicks, Declan G Murphy, Annette Haworth
Dosimetry of Lu-177-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
John Violet, Price Jackson, Justin Ferdinandus, Shahneen Sandhu, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Sue Ping Thang, Peter Eu, Mark Scalzo, Declan Murphy, Scott Williams, Rodney J Hicks, Michael S Hofman
Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma
Kaiji Fan, Cathrin Ritter, Paul Nghiem, Astrid Blom, Monique E Verhaegen, Andrzej Dlugosz, Niels Odum, Anders Woetmann, Richard W Tothill, Rodney J Hicks, Michael Sand, David Schrama, Dirk Schadendorf, Selma Ugurel, Juergen C Becker